Heart valves should satisfy the criteria of posing no risk to patients, as they are considered ‘life improving/life-saving’. There are currently no standards or regulations in place for handling, testing and decontaminating heart valves for transplants, leading to variations in laboratory practises of tissue banks. There is also a high discard rate of heart valves that can be transplanted due to failed microbiology. No External Quality Assessment (EQA) scheme for microbiology of heart valve tissue banking currently exists. The aim of the scheme will be to determine whether tissue banks can identify contaminants and successfully decontaminate the heart valves. This project is a follow up from the work carried out by the Scottish National Blood Transfusion Service (SNBTS).

Methods

Hearts valves are handled in accordance with the Human Tissue Act 2004. All activities associated to manipulating HV were recorded on the UKHSA Laboratory Information System (LIMS) to be able to process the tissue in the laboratory. The heart valves were processed in a MSC class II cabinet.

Sterility Checks

• The hearts valves were checked for bacterial growth by inoculating and incubating a small section of the valve on CBA and two wells cut in the agar to fill with transport fluid.
• The plates were then incubated at 37°C for 24 hrs and checked for any bacterial growth.

Neutralisation of Antibiotics

• Neutralisation step was performed with two different neutralising agents. The neutralisation effect of Biomerieux DNP-F and BD Peds Plus TM/F Bottle were compared to determine the suitable neutraliser for the heart valves.
• The heart valves were incubated at 37°C for 1 hr in neutralising solution and plated with fully susceptible Escherichia coli and Staphylococcus epidermidis to check for zone of inhibition around the inoculated area.
• The zone of inhibition indicates the presence of antibiotics (Figure 2).

Results

The heart valves did not contain organisms and were therefore considered sterile. No further work to decontaminate the heart valves was performed. The heart valves treated with Buffered Peptone Solution with Neutralizers (DNP-F) and the BD Peds Plus™/F show slight reduction in the zone size in comparison to the control (Tables 1 & 2).

Table 1: Results of the neutralisation step performed on Escherichia coli that failed to fully neutralise the antibiotics present in the HV. Comparison of the neutralisation between Control, Biomerieux DNP-F BD Peds Plus TM/F bottle

Table 2: Results of the neutralisation step performed on Staphylococcus epidermidis that failed to fully neutralise the antibiotics present in the HV. Comparison of the neutralisation between Control, Biomerieux DNP-F BD Peds Plus TM/F bottle

Discussion/Conclusion

The neutralising agents in Biomerieux DNP-F and BD Peds Plus TM/F bottles have not effectively neutralised antibiotics in the HV, possibly due to insufficient contact time. Further validation will be carried out to determine the correct time required for neutralisation. On successful neutralisation of the HV, the HV will then be spiked with bacteria and will be distributed as a specimen in a pilot study scheduled for November 2023.

The pilot study is firstly performed to determine the protocol is suitable and results are reproducible in tissue banks. Following successful delivery of the pilot, the scheme will then be launched.

Reference


Acknowledgements

Thank you to Sharon and Zahra from Tissues, Cells & Advanced Therapeutics (TCAT) Scottish National Blood Transfusion Service (SNBTS) for supplying the heart valves and assisting with the project.